BRIEF published on 11/05/2025 at 18:01, 11 months ago Christian Mias Appointed as New CEO of SCHOTT Pharma CEO Appointment SCHOTT Pharma Leadership Change Christian Mias Andreas Reisse
PRESS RELEASE published on 11/05/2025 at 17:56, 11 months ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Christian Mias to succeed Andreas Reisse as CEO SCHOTT Pharma AG & Co. KGaA appoints Christian Mias as CEO to succeed Andreas Reisse, effective May 1, 2026. Inside information disclosed. Press release via EQS News Inside Information CEO Appointment SCHOTT Pharma EQS News Christian Mias
BRIEF published on 08/12/2025 at 07:05, 1 year 1 month ago SCHOTT Pharma Reports Steady Q3 2025 Results Innovation SCHOTT Pharma High-value Solutions Drug Containment Q3 2025 Results
PRESS RELEASE published on 08/12/2025 at 07:00, 1 year 1 month ago SCHOTT Pharma delivers solid final third-quarter results SCHOTT Pharma reports solid Q3 2025 results with 1% revenue growth, 32.4% EBITDA margin, and strategic innovations Revenue Growth EBITDA Margin SCHOTT Pharma Innovations Q3 2025 Results
BRIEF published on 08/05/2025 at 10:00, 1 year 2 months ago SCHOTT Pharma's Q3 2025 Highlights and FY 2025 Outlook Revenue Growth EBITDA Margin Financial Outlook Q3 2025 High Value Solutions
BRIEF published on 08/05/2025 at 09:58, 1 year 2 months ago SCHOTT Pharma Updates FY 2025 Revenue and EBITDA Guidance Financial Results Revenue Growth EBITDA Margin SCHOTT Pharma FY 2025 Guidance
PRESS RELEASE published on 08/05/2025 at 09:55, 1 year 2 months ago SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance SCHOTT Pharma reports Q3 2025 revenues up 3% yoy at EUR 256m and gives FY 2025 guidance with EBITDA expected to be around 28.0%. Full financial results to be published on August 12, 2025 Revenues EBITDA SCHOTT Pharma Q3 2025 FY 2025 Guidance
PRESS RELEASE published on 08/05/2025 at 09:53, 1 year 2 months ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin SCHOTT Pharma AG & Co. KGaA specifies FY 2025 guidance for revenue growth and EBITDA margin, expecting 6.0% organic revenue growth and 28.0% EBITDA margin Revenue Growth EBITDA Margin SCHOTT Pharma Guidance FY 2025
BRIEF published on 06/11/2025 at 08:55, 1 year 3 months ago SCHOTT Pharma Extends CEO Contract and Appoints New CFO Global Expansion CEO Contract Extension Innovative Leadership New CFO Appointment Pharmaceutical Containment
PRESS RELEASE published on 06/11/2025 at 08:50, 1 year 3 months ago SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO SCHOTT Pharma extends CEO's contract Andreas Reisse & appoints Reinhard Mayer as CFO. Strategic personnel changes at SCHOTT Pharma AG & Co. KGaA CFO Appointment SCHOTT Pharma Personnel Changes CEO Contract Reinhard Mayer
Published on 10/05/2026 at 22:30, 7 hours 30 minutes ago EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 15 hours 15 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 15 hours 30 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 15 hours 30 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 16 hours ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/06/2026 at 03:00, 3 hours ago Qupital Unveils World’s First AI-Driven On-Chain E-Commerce Lending Protocol, Accelerating Web3 Global Trade Finance
Published on 10/05/2026 at 22:25, 7 hours 34 minutes ago LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Published on 10/05/2026 at 22:05, 7 hours 54 minutes ago AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Published on 10/05/2026 at 21:10, 8 hours 50 minutes ago Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Published on 10/05/2026 at 21:05, 8 hours 54 minutes ago EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Published on 10/05/2026 at 22:12, 7 hours 48 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 18:13, 11 hours 47 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 17:45, 12 hours 15 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 10/05/2026 at 17:45, 12 hours 15 minutes ago Declaration of voting rights at the end of September 2026
